Cataract volume outpaced historical trends, while refractive surgery missed expectations.
IRIS registry, US health policy also garner attention at biggest ophthalmic meeting of the year.
Top executives discussed their decision process for developing new technology in house or acquiring it.
Five of seven panelists at the ‘Cutting Edge’ symposium said they were not using FLCS technology, but they feel it has potential.
Product launches included Abbott’s introduction of its Whitestar Sovereign Pro; several early-stage companies showed manual capsulotomy devices.
Speakers described next-generation accommodating IOLs such as the Alcon/Google battery-operated and LensGen accommodating IOLs.
Alcon unveils Contoura Vision, the latest advancement in its WaveLight refractive portfolio.
The company expects an FDA advisory panel meeting will be scheduled in the coming months.
Retina specialist says new terminology is needed to describe some of the findings.
In anti-fibrosis pilot study, pretreatment with Fovista showed promise in patients with resistance to VEGF inhibition alone.
Only 21 percent of the audience at one session saw routine use of intraoperative OCT for macular surgery as useful.
Argus II is now being implanted at 31 centers worldwide; Alpha IMS team is discussing design of US feasibility study.
The company is targeting Q3-2016 for FDA approval.
The study is among Kass’ many contributions to glaucoma research.
The group said such commercials boost demand for expensive—and sometimes inappropriate—treatments, despite the clinical effectiveness of less costly alternatives.
Brent Saunders will become president and chief operating officer of the combined entity
Sun Pharma intends to use the acquisition to expand its eye care business in the US.
LENSAR developed the first femtosecond cataract laser that enabled automation of several elements of cataract surgery.
The firm reported long-term debt of $30.2 billion as of Sept. 30.
Novartis will unveil in January plans to spur growth in its eye care division.
A pre-existing agreement between the two firms made the move possible.
Ocata was previously named Advanced Cell Technology.
Mannin’s lead candidate, MAN-01, is a unique molecule delivered in an eye drop formulation.
Mark Baum unveiled a low-cost compounded version of the drug after learning of dramatic price increases by Turing.
Califf mostly received praise, though Sen. Bernie Sanders said he was unconvinced the cardiologist would take on drug makers over high prices.
Preliminary data suggested that 9 percent of ophthalmic surgeons currently offer the Dropless formula.
The drug, developed under the name Cyclokat, is the only ciclosporin eye drop licensed in the UK.
The unit also incorporates accommodation measurement and opacity observation of the optical media of the eye, the firm said.
You are not currently logged in.
©2017 Market Scope
Lost your Password